GERN Geron Corp

Price (delayed)

$4.905

Market cap

$2.91B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

$2.8B

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two ...

Highlights
The company's gross profit has surged by 119% QoQ and by 5% YoY
The revenue has soared by 119% from the previous quarter and by 5% YoY
The quick ratio has plunged by 58% YoY but it has grown by 16% from the previous quarter
GERN's debt has surged by 55% year-on-year
The net income has contracted by 34% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of GERN
Market
Shares outstanding
593.13M
Market cap
$2.91B
Enterprise value
$2.8B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.77
Price to sales (P/S)
5,692.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,394.16
Earnings
Revenue
$520,000
EBIT
-$191.57M
EBITDA
-$190.52M
Free cash flow
-$184.7M
Per share
EPS
-$0.35
Free cash flow per share
-$0.31
Book value per share
$0.63
Revenue per share
$0
TBVPS
$0.8
Balance sheet
Total assets
$482.07M
Total liabilities
$137.21M
Debt
$86.53M
Equity
$344.87M
Working capital
$328.35M
Liquidity
Debt to equity
0.25
Current ratio
3.67
Quick ratio
3.62
Net debt/EBITDA
0.55
Margins
EBITDA margin
-36,637.5%
Gross margin
100%
Net margin
-38,729.8%
Operating margin
-40,381.9%
Efficiency
Return on assets
-47.3%
Return on equity
-68.2%
Return on invested capital
-61.6%
Return on capital employed
-53.4%
Return on sales
-36,840.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GERN stock price

How has the Geron stock price performed over time
Intraday
4.14%
1 week
8.28%
1 month
0.72%
1 year
52.33%
YTD
132.46%
QTD
15.68%

Financial performance

How have Geron's revenue and profit performed over time
Revenue
$520,000
Gross profit
$520,000
Operating income
-$209.99M
Net income
-$201.4M
Gross margin
100%
Net margin
-38,729.8%
The company's gross profit has surged by 119% QoQ and by 5% YoY
The revenue has soared by 119% from the previous quarter and by 5% YoY
The operating margin has soared by 51% since the previous quarter but it has declined by 33% year-on-year
GERN's net margin has surged by 50% since the previous quarter but it is down by 28% year-on-year

Growth

What is Geron's growth rate over time

Valuation

What is Geron stock price valuation
P/E
N/A
P/B
7.77
P/S
5,692.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,394.16
Geron's EPS has decreased by 9% from the previous quarter
The P/B is 91% above the 5-year quarterly average of 3.9 and 55% above the last 4 quarters average of 4.8
Geron's equity has increased by 39% from the previous quarter and by 6% YoY
The revenue has soared by 119% from the previous quarter and by 5% YoY
The P/S is 31% above the last 4 quarters average of 4172.5

Efficiency

How efficient is Geron business performance
Geron's ROS has soared by 50% from the previous quarter but it has decreased by 28% YoY
GERN's ROE is up by 25% year-on-year but it is down by 8% since the previous quarter
Geron's ROIC has increased by 19% YoY but it has decreased by 15% from the previous quarter
The ROA has grown by 14% YoY but it has contracted by 6% from the previous quarter

Dividends

What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GERN.

Financial health

How did Geron financials performed over time
The quick ratio has plunged by 58% YoY but it has grown by 16% from the previous quarter
GERN's current ratio has dropped by 58% year-on-year but it is up by 16% since the previous quarter
GERN's debt is 75% smaller than its equity
GERN's debt has surged by 55% year-on-year
GERN's debt to equity is up by 47% YoY but it is down by 29% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.